A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)
Phase 4
Completed
- Conditions
- InfectionPneumonia
- Registration Number
- NCT00445094
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The primary objective of this study is a comparison between MK0787B and standard therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Greater than 18 years of age
- Patient is diagnosed with nosocomial pneumonia
Exclusion Criteria
- Immunological deficient patients
- Pregnant women and nursing mothers
- A fungus is identified before the study enrollment
- Received vancomycin or imipenem for more than 5 days before icu admission
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate MK0787B from standard-of-care antibiotics in ICU pneumonia treatment?
How does a de-escalating antibiotic strategy impact clinical outcomes compared to continuous broad-spectrum therapy in ICU pneumonia?
Which biomarkers correlate with improved patient response to MK0787B in ventilator-associated pneumonia subtypes?
What adverse event profiles distinguish MK0787B from other beta-lactamase inhibitor combinations in severe pneumonia?
How does Merck's MK0787B compare to other de-escalation protocols like Ceftolozane/Tazobactam in ICU-acquired pneumonia management?